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Hepatitis B virus (HBV) is highly endemic in sub-Saharan Africa, 
with >60% of the population contracting HBV and 8 - 20% becoming 
chronic carriers and at risk of life-threatening liver disease.[1] HBV 
and HIV share several transmission routes and are major causes 
of morbidity and mortality in Africa. In sub-Saharan Africa, the 
main HIV transmission routes are sexual transmission, mother-to-
child transmission and largely unexplained horizontal transmission 
between toddlers, with most infections occurring before the age of 
5 years.[2] Sexual transmission is the main route of HBV transmission 
in adolescence and early adulthood. Healthcare workers are also at 
risk of parenteral and percutaneous transmission during occupational 
exposure.
Chronic HBV infection is therefore frequent among people living 
with HIV/AIDS in sub-Saharan countries, with reported HBV 
surface antigen (HBsAg) seroprevalence rates of 7 - 15% in West 
Africa[3,4] and East Africa.[5,6]
Before the introduction of antiretroviral therapy (ART), HBV/
HIV-coinfected individuals were likely to die from the clinical 
consequences of HIV infection. However, since the introduction of 
ART, the proportion of deaths due to HBV-associated end-stage liver 
disease (ESLD) has increased[7] because progression of HBV infection 
towards cirrhosis, ESLD and hepatocellular carcinoma is more rapid 
in HIV-coinfected patients.[8]
In 2010, the World Health Organization (WHO) recommended 
HBV screening before ART initiation, and the use of ART regimens 
containing tenofovir plus either lamivudine or emtricitabine for HIV/
HBV coinfection.[9] However, HBV screening may be unavailable in 
resource-limited settings, and lamivudine is often the only available 
drug active against HBV in sub-Saharan African countries. Use of 
lamivudine without tenofovir has been linked to gradual emergence 
of resistance mutations in the HBV polymerase gene.[10] The annual 
incidence of viral mutations in this setting has been estimated at 
about 22%, the main risk factor being high HBV viral load at ART 
initiation.[11] In contrast, no cases of HBV resistance have been 
described in tenofovir-treated patients.
In 2011, there were 103 HIV/AIDS care centres managing 80 000 
patients in Togo, of whom 36 700 were receiving highly active ART. 
Expanded access to ART, combined with sustainable preventive 
interventions such as condom provision and health information, have 
reduced HIV-related morbidity and mortality in Togo.[12] In 2011, 
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Background. No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely 
tested for HBV infection.
Objectives. To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected 
patients in Togo.
Method. This cross-sectional study was carried out in Lomé, Togo, from January 2010 to December 2011 among HIV-infected patients who 
had been on antiretroviral therapy (ART) for at least 6 months.
Results. In total, 1 212 patients (74.9% female) living with HIV/AIDS and treated with ART were included in the study. The seroprevalence 
of hepatitis B surface antigen (HBsAg) was 9.7% (117/1 212; 95% confidence interval (CI) 8.04 - 11.45). Of these 117 HBsAg-positive 
patients, 16 (13.7%) were hepatitis B e-antigen (HBeAg)-positive, and 115 (98.3%) were on lamivudine. The HBV DNA load was >10 IU/
mL in 33/117 patients overall (38%), and in 87.5% of 16 HBeAg-positive patients (p<0.0001). In multivariate analysis, factors associated 
with HBV DNA load >10 IU/mL were HBeAg positivity (adjusted odds ratio (aOR) 6.4; p=0.001) and a higher level of education (aOR 6.5; 
p=0.026). The prevalence of HBV resistance to lamivudine was 13.0% (15/115; 95% CI 7.0 - 19.0). The detected resistance mutations were 
rtL180M (14/15 patients) and rtM204V/I (15/15).
Conclusion. The seroprevalence of HBV among ART-treated HIV-infected patients in Togo was 9.7%. The prevalence of HBV lamivudine 
resistance mutations after 2 years of ART was 13.0%. These results suggest that HBV screening before ART initiation can be based on 
HBsAg testing.
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national guidelines[13] recommended first-
line therapy with stavudine, or zidovudine 
and lamivudine, plus either nevirapine or 
efavirenz. Tenofovir is available for second-
line therapy in the case of treatment failure 
or severe anaemia caused by zidovudine.
No data are available on HIV/HBV or 
hepatitis C virus (HCV) coinfection in Togo, 
and patients are not routinely tested for HBV 
infection. National guidelines recommend 
HBV screening only when the alanine 
aminotransferase (ALT) level is more than 
three times higher than normal.[13]
Objectives
To determine the prevalence of HBV 
infection among HIV-infected patients 
in Togo, and the effect of lamivudine-
containing ART on HBV replication and 
resistance.
Methods
Study design and setting
We conducted an analytical cross-sectional 
study in four HIV/AIDS care centres in 
Lomé, Togo, namely the Department of 
Pneumology and Infectious Diseases of 
Sylvanus Olympio teaching hospital and 
three centres run by non-governmental 
organisations: Aide Médicale et Charité 
(AMC), Association de Bien Etre Familial 
(ATEBF), and Espoir Vie Togo (EVT).
Study population
We studied HIV-infected patients aged ≥18 
years who had been taking ART for at least 
6 months and had not stopped taking their 
treatment for more than 3 months. The 
study flow chart is shown in Fig. 1.
Clinical investigations
Data were collected through a question-
naire-assisted interview and included socio-
demographic information (sex, age, height, 
weight, nationality, partnership status, 
education, occupation) and medical infor-
mation (history of blood transfusion and 
intramuscular (IM) and intravenous (IV) 
injections, alcohol consumption, pre-ART 
and current CD4 cell counts and HIV viral 
load if available, date of HIV diagnosis, date 
of first ART, current ART regimen, and 
treatment adherence). WHO criteria were 
used to determine the clinical stages of HIV 
infection.[9]
Laboratory investigations
Blood samples were taken from each 
participant for liver enzyme assay and a CD4 
cell count. Serum (7 mL) and plasma (14 mL) 
samples were stored at –20°C until testing 
in the molecular biology and immunology 
laboratory (BIOLIM) of the Lomé Faculty of 
Medicine and Pharmacy.
HIV and HBV viral loads for patients 
with HBsAg were measured at the BIOLIM 
laboratory in Lomé and the virology labor-
atory at Cochin Hospital, Paris, France. 
ALT, aspartate aminotransferase (AST) and 
gamma-glutamyl transpeptidase (GGT) 
were assayed using standard methods. The 
upper normal limits of ALT and AST levels 
were both 40 IU/L. CD4 cells were counted 
by flow cytometry on a Becton Dickinson 
FACSCalibur device (Becton Dickinson, 
USA). Screening for HBV infection was based 
on HBsAg detection; positive samples were 
tested for hepatitis B e-antigen (HBeAg) and 
anti-HBe antibodies. Samples negative for 
HBsAg were screened for antibodies to HBsAg 
and hepatitis B core antigen (HBcAg). Sero-
logical tests were performed with enzyme-
linked immunosorbent assay methods using 
reagents from DIASource (Belgium).
Participants who tested negative for 
all HBV markers were classified as HBV-
susceptible, those who were positive for 
both anti-HBc and anti-HBs were classified 
as having been exposed to HBV, and those 
who were anti-HBc-negative and anti-
HBs-positive were classified as probably 
vaccinated.
Samples positive for HBsAg were tested 
for HIV and HBV viral load. HIV viral 
load was determined with a polymerase 
chain reaction (PCR) method targeting the 
polymerase gene (Abbott Real Time HIV, 
Abbott Diagnostics, France). HBV viral load 
was determined with a PCR method (Abbott 
Real Time HBV, Abbott Laboratories, USA). 
Results were expressed in IU/mL and log10 
copies/mL. HBV DNA loads <10 IU/mL 
were classified as undetectable.
Samples positive for both HBsAg and HBV 
DNA were HBV genotyped by phylogenetic 
methods, and the HBV polymerase gene 
was sequenced to detect mutations known 
to be associated with lamivudine resistance 
(rtV173L, rtV180M, rtA181T/V, rtT184G 
and rtM204V/I) using Bioedit software 
(http//:www.mbio.ncsu.edu/bioedit).
Ethical issues
The study was designed and implemented in 
accordance with the Declaration of Helsinki 
and approved by the Comité Bioéthique 
pour la Recherche en Santé (CBRS) (Ref. 
No. 006/2009/CBRS, 12 November 2009) 
before implementation. The patients gave 
their written informed consent, recorded in 
a form, for their data to be used for the study. 
The HBsAg, CD4 cell count and HIV viral 
load results were given to each patient by a 
doctor in a private room in the clinic.
Statistical analysis
Baseline values of continuous variables were 
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Fig. 1. Flow chart of patients included in the study.
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and categorical variables as frequencies and 
percentages.
The χ2 test or Fisher’s exact test were 
used as appropriate for bivariate analysis 
of categorical variables, and the Mann-
Whitney test was used for continuous 
variables. The main endpoint was the 
prevalence of HIV/HBV coinfection, HBV 
infection being defined by the presence of 
HBsAg. Multivariate backwards stepwise 
logistic regression was used to identify 
factors independently associated with 
active HBV replication (HBV DNA >10 IU/
mL). All variables significant in bivariate 
analysis (p<0.05) and variables with p-values 
<0.1 were included in the model. We then 
removed variables that were not significant 
at a p-value of <0.05, in stepwise fashion. 
We also assessed the significance of the 
likelihood ratio of the test. No interaction 




From April to December 2011, we enrolled 
1 212 HIV-infected patients (mean age 
41  years, range 21 - 79). Table 1 shows the 
socio demographic, immunovirological and 
hepatic characteristics of the study popu-
lation. Females represented 74.9% of the 
patients (n=908). Five hundred and eighty-
two patients (48.0%) were living with a 
partner, 598 (49.3%) had attended secondary 
school, 1 043 (86.1%) had received at least 
one IM or IV injection, 209 (17.2%) had 
received a blood transfusion, and 25 (2.1%) 
reported HBV vaccination.
AST and ALT levels ranged from 35 to 
364  IU/L and from 30 to 264 IU/l, respec-
tively. The median CD4 cell count was 143/
µL (interquartile range (IQR) 63 - 205).
One thousand and eighty patients (89.1%) 
were on a first-line ART regimen comprising 
two nucleoside reverse transcriptase inhi-
bitors and one non-nucleoside reverse 
transcriptase inhibitor, and 123 patients 
(10.1%) were on second-line ART. Most 
patients were on at least one antiretroviral 
drug active against HBV: lamivudine in 
1 092 cases (90.1%) and tenofovir in 110 
(9.1%).
Prevalence of HBV markers
Serological tests showed that 48.3% of the 
patients (585/1 212) had been  ex posed to 
HBV; of the 1 212 patients, 117 (9.7%) 
were HBsAg-positive, 243 (20.0%) were 
anti-HBs- and anti-HBc-positive, and 498 
(41.1%) were only anti-HBc-positive. Six-
teen patients (1.3%) were only anti-HBs-
positive and were considered as vaccinated 
against HBV, while 337 patients (27.8%) 
were negative for all the serological markers 
of HBV infection and were categorised as 
HBV-susceptible.
Of the 117 patients who were HBsAg-posi-
tive, 16 (13.7%) were also HBeAg-positive, 
86 (73.5%) were also anti-HBe-positive, and 
15 (12.8%) had neither HBe marker.










Age (years), median (IQR) 40.8 (34.1 - 47.8.) 37.9 (32.4 - 44.9) 40.8 (34.7 - 47.9)
Males, n (%) 304 (25.1) 31 (26.5) 273 (24.9)
Partnership status, n (%)
One of a couple 582 (48.0) 50 (42.7) 532 (48.6)
Alone 630 (52.0) 67 (57.3) 563 (51.4)
Education level, n (%)
No school or primary 614 (50.7) 54 (46.2) 560 (51.1)
Secondary or higher 598 (49.3) 63 (53.8) 535 (48.9)
Income-generating activity, n (%) 998 (82.3) 97 (82.9) 901 (82.3)
Body weight (kg), median (IQR) 63 (55 - 72) 61 (55 - 68) 63 (55 - 72)
Alcohol consumption, n (%) 350 (28.9) 36 (30.8) 314 (28.7)
Transfusion of blood products, n (%) 209 (17.2) 26 (22.2) 183 (16.7)
IV or IM injection, n (%) 1 043 (86.1) 104 (88.9) 939 (85.7)
Immunovirological characteristics
CD4 cell nadir (/µL), median (IQR) 142 (63 - 205) 139 (54 - 193) 142 (65 - 207)
Last CD4 count (/µL), median (range) 338 (216 - 474) 313 (183 - 427) 340 (219 - 479)
Last CD4 cell count (/µL), n (%)
<200 362 (29.9) 44 (37.6) 318 (29.1)
200 - 350 336 (27.7) 31 (26.4) 305 (27.9)
>350 514 (42.4) 42 (35.9) 472 (43.1)
HIV RNA (copies/mL), median (IQR) 40 (0 - 975) 40 (0 - 5 915) 40 (0 - 185)
HIV RNA values (copies/mL, n =117), n (%)
<40 - 43 (36.7) -
>40 - 74 (63.3) -
WHO stage of HIV, n (%)
1 or 2 831 (68.6) 80 (68.4) 751 (68.6)
3 or 4 381 (31.4) 37 (31.6) 344 (31.4)
Ongoing antiretroviral treatment, n (%) 1 212 (100.0) 117 (100.0) 1 003 (91.6)
Type of antiretroviral treatment, n (%)
1st-line therapy 1 080 (89.1) 108 (92.3) 972 (88.8)
2nd-line therapy 123 (10.1) 9 (7.7) 114 (10.4)
 Containing lamivudine or 
emtricitabine
1 102 (90.9) 115 (98.3) 987 (90.1)
Containing tenofovir 110 (9.1) 9 (7.7) 101 (9.2)
Duration of antiretroviral treatment 
(months), mean (range)
31.0 (18.2 - 57.6) 30.2 (19.1 - 38.9) 32.6 (18.2 - 57.1)
Hepatic status
ALT (IU/mL), median (range) 30 (5 - 264) 28 (8 - 174) 29 (6 - 232)
Hepatic decompensation, n (%) 16 (1.3) 1 (0.8) 15 (1.4)
Vaccinated against HBV, n (%) 25 (2.1) 7 (6.1) 18 (1.6)
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Active HBV replication
Among the 117 HIV/HBV-coinfected 
patients, 115 (98.3) were on lamivudine. 
HBV DNA loads were >10 IU/mL in 33/117 
(28.2%) of these patients and 84/117 (71.8%) 
had HBV DNA loads <10 IU/mL. Of the 16 
HBeAg-positive patients, 14 (87.5%) had 
HBV DNA loads >10 IU/mL(p<0.0001), 
while 12 (75%) had HBV DNA loads 
>1 500 IU/mL.
In bivariate analysis, active HBV repli-
cation was associated with >24 months 
of ART (odds ratio (OR) 1.02; p=0.045) 
and HBeAg positivity (OR 22.7; p<0.0001) 
(Table 2).
In multivariate analysis, two factors 
were significantly associated with active 
HBV replication, namely HBeAg positivity 
(6.4-fold increase; adjusted OR (aOR) 6.4; 
p=0.001), and a higher level of education 
(aOR 6.5; p=0.026) (Table 3).
HBV resistance mutations
The prevalence of HBV resistance to lami-
vudine was 13.0% (15/115; 95% CI 7.0 - 
19.0). Genotyping was successful in 24 of 
the 33 patients with active HBV replication, 
all 24 having HBV DNA loads >2 000 IU/
mL. Genotype E was found in all 24 patients. 
HBV resistance mutations to lamivudine 
were detected in 15/23 patients (65.2%; 95% 
CI 48.7 - 87.7), and consisted of rtL180M in 
14 cases and rtM204V/I in 15.
Discussion
The prevalence of chronic HBV infection, 
based on the presence of HBsAg, was 
9.7% among HIV-infected adults receiving 
ART in Lomé, Togo, while 48.3% of the 
study population had serological evidence 
of exposure to HBV. Among HIV/HBV-
coinfected patients positive for HBsAg, 13.7% 
were also positive for HBeAg. Of the 117 
HBV-coinfected patients, 98.3% were on an 
antiretroviral regimen in which lamivudine 
was the only drug active on HBV. Active 
HBV replication was detected in 33 (28.2%) 
of these 117 patients. The prevalence of 
HBV genotypic resistance to lamivudine was 
65.2% (15/23 successfully tested patients). 
The only resistance mutations in the HBV 
polymerase gene were rtL180M (14/15) and 
rtM204V/I (15/15).
Prevalence of HBV infection  
and HBeAg
The prevalence of chronic HBV infection 
among HIV-coinfected patients in our 
study was similar to that observed in the 
general population of Burkina Faso.[14] 
The situation in Togo is therefore quite 
different from that reported in European 
countries, where chronic HBV infection 
is about ten times more prevalent among 
HIV-infected people than in the general 
population. In France, for example, the 
prevalence of chronic HBV infection is 7% 
among HIV-infected persons and only 0.7% 
in the general population.[15,16] The profile 
of infection in Togo suggests that HBV 
is usually acquired in childhood, before 
acquisition of HIV infection.
HBeAg may be present or absent in patients 
with chronic hepatitis B.[17] The generally 
long duration of HBV infection in Togolese 
individuals explains why most of them are 
HBeAg-negative and have relatively low 
HBV DNA loads, and why some are healthy 
carriers with no ongoing HBV replication. 
This was also the case in a recent study 
conducted in Abidjan, Côte d’Ivoire, where 
33% of HIV/HBV-coinfected patients were 
Table 2. Factors associated with active HBV replication (HBV DNA >10 IU/mL)
Variable OR 95% CI p-value
Age (years) 1.02 0.96 - 1.10 0.52
CD4 cell count before ART (/µL) 0.99 0.98 - 1.00 0.44
Last CD4 cell count 1.00 0.99 - 1.00 0.86
Duration of ART (months) 1.02 1.00 - 1.04 0.045
Type of antiretroviral treatment 0.98
1st-line therapy 1 1
2nd-line therapy 0.01 0.01 - 99.99
Sex 0.55
Male 1 1
Female 0.70 0.22 - 2.25
Education level 0.10
No school or primary 1 1
Secondary or higher 2.75 0.82 - 9.22
HBeAg status <0.0001
Negative 1 1
Positive 22.75 6.06 - 86.42
HIV viral load 0.73
Detectable (>40 IU/mL) 1 1
Undetectable 0.82 0.26 - 2.57
CD4 cell count before ART (/µL) 0.51
<200 1 1
≥200 0.48 0.05 - 4.30
Last CD4 cell count(/µL) 0.59
<200 1 1
200 - <350 2.17 0.49 - 9.64
≥350 1.49 0.34 - 6.50
Table 3. Factors independently associated with HBV replication (HBV DNA >10 IU/
mL) among 117 HIV/HBV-coinfected patients
Variable aOR 95%CI p-value
Duration of ART 1.0 0.9 - 1.1 0.074
Education level 0.026
No school or primary 1 1
Secondary or higher 6.5 1.2 - 34.1
HBeAg status 0.001
Negative 1 1
Positive 6.4 2.1 - 19.5 
RESEARCH
638       June 2016, Vol. 106, No. 6
healthy carriers of HBV, being HBsAg-positive but HBV DNA-
negative.[18] Studies in other sub-Saharan African countries have also 
shown that most HBV-infected patients are HBeAg-negative.[17]
Prevalence of anti-HBc 
Anti-HBc was the only serological marker of HBV exposure in 41.1% 
of our patients. Previous studies of HIV-coinfected patients have also 
shown a high prevalence of isolated anti-HBc positivity, ranging from 
24.5% to 37.8%.[19-21] In a recent study conducted in Spain, isolated 
anti-HBc positivity was associated with younger age and anti-HCV 
antibodies,[22] but those two factors were not analysed in our study.
Active HBV replication in HBsAg-positive patients
After a median of 31 months on ART, 71.8% of patients with chronic 
HBV infection had HBV DNA suppression when their ART regimen 
contained lamivudine. Only 28.2% of the patients with chronic HBV 
infection had HBV DNA levels indicating active repli cation, and the 
main factor associated with HBV replication was the presence of 
HBeAg. It has been reported that 48 weeks of combined tenofovir-
lamivudine therapy is often too short to achieve undetectable HBV 
DNA in HIV/HBV-coinfected patients, despite undetectable HIV 
viraemia. This was explained by associated factors such as positive 
HBeAg and high baseline HBV DNA.[23]
Our results are also consistent with the findings of a recent study 
performed in Thailand, where the rate of HBV DNA suppression in 
HIV/HBV-coinfected patients was 67% after 48 weeks of lamivudine-
containing ART and in which HBV breakthrough was exclusively 
observed in HBeAg-positive patients.[24]
In contrast to other studies,[25] neither the duration of ART nor 
active HIV replication was associated with HBV replication in our 
study. The presence of HBeAg is a fairly reliable marker of HBV 
replication. In fact, at the initiation of ART, HBV and HIV/HBV 
coinfection markers were not determined in our study. Furthermore, 
98.3% of patients in our study were receiving ART containing 
only lamivudine. It is known that the HBV viral load is related to 
the presence of HBeAg,[4] and lamivudine alone is less effective in 
reducing the HBV viral load.[26,27]
We also found that a higher level of education was associated 
with active HBV replication. This may be because patients with 
a lower level of education tend to acquire HBV infection earlier 
during childhood, through horizontal transmission among toddlers, 
and have therefore lost HBeAg, whereas patients with a higher 
level of education tend to acquire HBV later in life through sexual 
exposure. Low socioeconomic status and poor hygiene are commonly 
associated with a higher risk of HBV infection.[28]
Prevalence of HBV resistance to lamivudine
The prevalence of HBV resistance to lamivudine usually reaches 40 - 
50% after 2 years of treatment in studies of Western cohorts of HIV/
HBV-coinfected individuals taking lamivudine as the only drug active 
against HBV,[10,29] whereas prevalence rates <15% have been reported in 
similar populations in sub-Saharan Africa. This discrepancy could be 
related mainly to differences in the timing of HBV infection relative to 
HIV infection, or less probably to the fact that African studies usually 
involved shorter follow-up (24 months). A cross-sectional study in 
Cameroon found resistance mutations in 13% of 54 patients at 24 
months.[30] A retrospective analysis in the Gambia found lamivudine 
resistance mutations in 14% of 21 patients followed up for between 6 
and 56 months.[31] In two recent prospective cohort studies conducted 
in Nairobi, Kenya, lamivudine resistance occurred in only 9.5% of 
27 coinfected patients after 18 months of therapy[32] and in only one 
of 159 women followed up for a median of 3.4 years.[33]
Conclusion
After a median of 31 months on ART, 28.2% of HIV-infected 
patients with chronic HBV coinfection had active HBV replication. 
HBeAg positivity was associated with HBV replication and with the 
occurrence of HBV resistance mutations. These findings suggest that 
a two-step approach may be suitable for HBV screening of HIV-
infected patients prior to ART initiation in resource-limited settings, 
consisting of HBsAg screening in all patients and HBeAg screening 
of patients positive for HBsAg.
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